COMPARING HOE 901 INSULIN W/ NPH HUMAN INSULIN FOR TYPE II DIABETES

HOE 901 胰岛素与 NPH 人胰岛素治疗 II 型糖尿病的比较

• 批准号: 6265105
• 负责人: CHARLES J CLARK
• 金额: $ 0.04万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265105
• 关键词: clinical research; clinical trial phase I; diabetes mellitus therapy; human subject; human therapy evaluation; insulin; noninsulin dependent diabetes mellitus; slow release drug

This clinical research study involves a new, genetically-modified insulin, HOE 901. This modification gives this insulin a longer duration of action and the ability to provide a more stable insulin supply, therefore, offering diabetics more optimal blood sugar levels. Research has documented that high blood sugar levels place individuals at high risk for complications such as nerve, eye, vascular and kidney disease. This study will compare HOE 901 to a standard, commercially available insulin preparation.

这项临床研究涉及一种新的转基因胰岛素HOE 901。这一改进使这种胰岛素的作用时间更长，并能够提供更稳定的胰岛素供应，因此为糖尿病患者提供更理想的血糖水平。研究证明，高血糖水平会使个人面临神经、眼睛、血管和肾脏疾病等并发症的高风险。这项研究将HOE 901与一种标准的商业胰岛素制剂进行比较。